Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study
暂无分享,去创建一个
G. Kazemier | J. Tuynman | B. Ylstra | M. Kusters | D. Pegtel | P. Eijk | D. Heideman | N. V. van Grieken | S. Vlek | Jamie J Beagan | N. Sluiter | S. Bach
[1] D. Moro,et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] S. Sleijfer,et al. RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer , 2019, Molecular oncology.
[3] G. Kazemier,et al. Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review , 2019, JNCI cancer spectrum.
[4] S. Shchegrova,et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.
[5] A. Zwinderman,et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6) , 2019, BMC Cancer.
[6] E. Oki,et al. A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer , 2019, British Journal of Cancer.
[7] M. Pocard,et al. A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7. , 2019, European Journal of Surgical Oncology.
[8] S. Lippman,et al. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival , 2019, JCO precision oncology.
[9] F. De Keyzer,et al. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases , 2019, Cancer Imaging.
[10] U. Sarpel,et al. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience , 2018, Annals of Surgical Oncology.
[11] R. Beets-Tan,et al. Diffusion‐weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery , 2018, The British journal of surgery.
[12] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[13] K. Spindler,et al. Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing , 2018, Translational oncology.
[14] R. Kurzrock,et al. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival , 2018, Annals of Surgical Oncology.
[15] M. Pocard,et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. , 2018, Journal of Clinical Oncology.
[16] G. Kazemier,et al. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC , 2018, Annals of Surgical Oncology.
[17] D. Elias,et al. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG‐RENAPE) , 2018, The British journal of surgery.
[18] A. Aalbers,et al. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2018, Annals of Surgical Oncology.
[19] K. Kinzler,et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study , 2018, Gut.
[20] M. O'Leary,et al. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy , 2017, JAMA surgery.
[21] H. Lang,et al. Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection , 2017, Scientific Reports.
[22] J. Albanell,et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] C. Tournigand,et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.
[24] Rebecca M. Dodson,et al. Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy , 2016, Annals of Surgical Oncology.
[25] Bauke Ylstra,et al. Sequencing Structural Variants in Cancer for Precision Therapeutics. , 2016, Trends in genetics : TIG.
[26] J. Esquivel. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. , 2016, Journal of gastrointestinal oncology.
[27] S. Nishizuka,et al. Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel , 2016, PloS one.
[28] H. Nielsen,et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery , 2015, Gut.
[29] A. Mirnezami,et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone , 2014, British Journal of Cancer.
[30] P. Snijders,et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology , 2014, Cellular Oncology.
[31] M. Wiezer,et al. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer , 2014, Journal of surgical oncology.
[32] I. Nagtegaal,et al. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[34] K. Havenga,et al. Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol , 2013, Annals of Surgical Oncology.
[35] H. Bonjer,et al. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. , 2013, Cancer treatment reviews.
[36] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[37] N. Gusani,et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis , 2010, Cancer.
[38] C. Meijer,et al. A Panel of High Resolution Melting (HRM) Technology-Based Assays with Direct Sequencing Possibility for Effective Mutation Screening of EGFR and K-ras Genes , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[39] S. Bruin,et al. 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer , 2008, Annals of Surgical Oncology.
[40] W. Oyen,et al. Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies , 2006, Annals of surgery.
[41] F. Zoetmulder,et al. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[42] H. van Tinteren,et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] D. Jayne,et al. Peritoneal carcinomatosis from colorectal cancer , 2002, The British journal of surgery.
[44] M. Duffy,et al. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.
[45] P. Sugarbaker. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. , 1998, Seminars in surgical oncology.
[46] K. Jablonski,et al. Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.
[47] B. Glimelius,et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. , 2016, European journal of cancer.
[48] M. Ducreux,et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. , 2014, European journal of cancer.
[49] B. Ylstra,et al. High-resolution copy number profiling by array CGH using DNA isolated from formalin-fixed, paraffin-embedded tissues. , 2012, Methods in molecular biology.
[50] D. Elias,et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] M. Bracke,et al. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. , 2009, The Lancet. Oncology.
[52] M. P. Tristan D. Yan BSc,et al. Evaluation of Preoperative Computed Tomography in Estimating Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis , 2008, Annals of Surgical Oncology.
[53] A. Witkamp,et al. Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin , 2004, Annals of Surgical Oncology.